Next-Generation Care for Patients With Bladder Cancer

This program is intended for NPs, PAs, and other healthcare professionals caring for patients with bladder cancer.

The goal of this activity is to improve the knowledge, confidence, and skills of NPs/PAs who care for patients with bladder cancer on the latest updates in guideline-directed and evidence-based medicine, therapeutic management, and strategies to improve health equity, ultimately improving clinical outcomes for their patients.

• Evaluate current and emerging evidence for targeted and immunotherapies in bladder cancer—including non–muscle-invasive, muscle-invasive, locally advanced, and metastatic disease—considering impact of toxicity profiles, prognostic variables, comorbidities, treatment duration, and patient preference

• Plan optimal medical and pharmacologic management strategies for patients with bladder cancer on immune checkpoint inhibitors, targeted therapies, chemotherapy, or gene therapy to manage treatment-related adverse events

• Counsel individual patients with bladder cancer on the potential for enrollment in ongoing clinical trials investigating novel therapies or treatment combinations

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit. 

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until May 15, 2025. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships. 

Primary Author

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, CTI/SOBI, Daichii Sankyo, Lilly, Morphosys, Pfizer.